Tags

Type your tag names separated by a space and hit enter

Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours.
J Surg Oncol. 2005 Dec 15; 92(4):337-43.JS

Abstract

BACKGROUND

We examined the expression of apoptosis-related proteins in serous versus mucinous borderline ovarian tumours, in comparison with benign and malignant ovarian tumours.

MATERIALS AND METHODS

Immunohistochemical expression of pro-apoptotic (p53, p21, bax, bak, fas) and anti-apoptotic proteins (bcl-2, bcl-x) was determined in 34 borderline (19 mucinous, 15 serous), 20 benign (10 mucinous, 10 serous) and 28 malignant ovarian tumours (9 mucinous, 19 serous).

RESULTS

A difference in semi-quantitative p53 expression was found between benign and borderline tumours (P = 0.01), but not between borderline and malignant tumours. Increased p21 expression was found in borderline versus benign tumours (P = 0.004). Bcl-2 expression was lower in borderline than in benign (P = 0.01) and malignant tumours (P = 0.02). No difference in bax, bak, fas or bcl-x expression was observed among the three tumour types. Higher percentage of p21 positive cells was found in serous than in mucinous borderline tumours (P < 0.001). Bcl-2 expression was higher in serous than in mucinous forms of benign (P < 0.001), borderline (P < 0.001), and malignant tumours (P < 0.003). No difference in p53, bax, bak, fas or bcl-x expression was observed between serous and mucinous borderline ovarian tumours.

CONCLUSION

Although p53 overexpression was a common feature of both mucinous and serous borderline tumours, p21 and bcl-2 overexpression appeared specific to serous tumours.

Authors+Show Affiliations

Service de Gynécologie-Obstétrique, Hôpital Tenon, AP-HP, CancerEst, Université Pierre et Marie Curie Paris VI, Paris, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

16299808

Citation

Fauvet, Raffaèle, et al. "Expression of Pro-apoptotic (p53, P21, Bax, Bak and Fas) and Anti-apoptotic (bcl-2 and Bcl-x) Proteins in Serous Versus Mucinous Borderline Ovarian Tumours." Journal of Surgical Oncology, vol. 92, no. 4, 2005, pp. 337-43.
Fauvet R, Dufournet C, Poncelet C, et al. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours. J Surg Oncol. 2005;92(4):337-43.
Fauvet, R., Dufournet, C., Poncelet, C., Uzan, C., Hugol, D., & Daraï, E. (2005). Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours. Journal of Surgical Oncology, 92(4), 337-43.
Fauvet R, et al. Expression of Pro-apoptotic (p53, P21, Bax, Bak and Fas) and Anti-apoptotic (bcl-2 and Bcl-x) Proteins in Serous Versus Mucinous Borderline Ovarian Tumours. J Surg Oncol. 2005 Dec 15;92(4):337-43. PubMed PMID: 16299808.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours. AU - Fauvet,Raffaèle, AU - Dufournet,Charlotte, AU - Poncelet,Christophe, AU - Uzan,Catherine, AU - Hugol,Danièle, AU - Daraï,Emile, PY - 2005/11/22/pubmed PY - 2006/1/4/medline PY - 2005/11/22/entrez SP - 337 EP - 43 JF - Journal of surgical oncology JO - J Surg Oncol VL - 92 IS - 4 N2 - BACKGROUND: We examined the expression of apoptosis-related proteins in serous versus mucinous borderline ovarian tumours, in comparison with benign and malignant ovarian tumours. MATERIALS AND METHODS: Immunohistochemical expression of pro-apoptotic (p53, p21, bax, bak, fas) and anti-apoptotic proteins (bcl-2, bcl-x) was determined in 34 borderline (19 mucinous, 15 serous), 20 benign (10 mucinous, 10 serous) and 28 malignant ovarian tumours (9 mucinous, 19 serous). RESULTS: A difference in semi-quantitative p53 expression was found between benign and borderline tumours (P = 0.01), but not between borderline and malignant tumours. Increased p21 expression was found in borderline versus benign tumours (P = 0.004). Bcl-2 expression was lower in borderline than in benign (P = 0.01) and malignant tumours (P = 0.02). No difference in bax, bak, fas or bcl-x expression was observed among the three tumour types. Higher percentage of p21 positive cells was found in serous than in mucinous borderline tumours (P < 0.001). Bcl-2 expression was higher in serous than in mucinous forms of benign (P < 0.001), borderline (P < 0.001), and malignant tumours (P < 0.003). No difference in p53, bax, bak, fas or bcl-x expression was observed between serous and mucinous borderline ovarian tumours. CONCLUSION: Although p53 overexpression was a common feature of both mucinous and serous borderline tumours, p21 and bcl-2 overexpression appeared specific to serous tumours. SN - 0022-4790 UR - https://www.unboundmedicine.com/medline/citation/16299808/Expression_of_pro_apoptotic__p53_p21_bax_bak_and_fas__and_anti_apoptotic__bcl_2_and_bcl_x__proteins_in_serous_versus_mucinous_borderline_ovarian_tumours_ L2 - https://doi.org/10.1002/jso.20424 DB - PRIME DP - Unbound Medicine ER -